Ziopharm's darinaparsin gets orphan-drug status from the FDA

09/23/2010 | Fox Business

The FDA granted orphan-drug designation to darinaparsin, Ziopharm Oncology's treatment for peripheral T-cell lymphoma. The company plans to launch a Phase I study in late 2011 to test the tolerability of the drug when combined with standard treatment.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC